The Cancer Letter

Inside information on cancer research and drug development

Capitol Hill

ARPA-H, the key element of Biden cancer agenda, faces uncertain future

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

President Biden has been describing the Advanced Research Projects Agency for Health (ARPA-H), a DARPA-like biomedical research agency, as the centerpiece of his effort to “end cancer as we know it.”

Alas, in the heat of the FY22 appropriations process, the proposed NIH agency that would enable the rapid development of high-risk, high-reward projects is itself at high risk of not being authorized and funded.

In a markup July 12, the House Appropriations Subcommittee on Labor, Health, & Human Services voted to appropriate $3 billion for ARPA-H and an increase of $3.5 billion for the rest of NIH (The Cancer Letter, July 16, 2021). This raise falls short of President Biden’s request of $6.5 billion over three yearsfor ARPA-H, but provides a greater budget increase than requested by the president for NIH institutes and centers. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Alice Tracey
Alice Tracey
Reporter
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

Roger Lo awarded $2M NIH grant to study melanoma treatment resistance

Roger Lo, professor of medicine, dermatology, and molecular and medical pharmacology and investigator at the UCLA Health Jonsson Comprehensive Cancer Center, was awarded a $2 million grant from NIH to investigate innovative strategies to prevent drug resistance in melanoma treatment and improve the effectiveness of MAPK inhibitors, a common treatment for patients with melanomas that carry the BRAFV600 mutation.
Clinical Roundup

NIH study links neighborhood environment to prostate cancer risk in men with West African genetic ancestry

West African genetic ancestry was associated with increased prostate cancer among men living in disadvantaged neighborhoods but not among men living in more affluent neighborhoods, according to a new study led by NIH researchers. The findings suggest that neighborhood environment may play a role in determining how genetic ancestry influences prostate cancer risk. 
Byline
Alice Tracey
Alice Tracey
Reporter
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account